CoChat

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.

Abstract

Background Depression is common in patients with Parkinson's disease, but evidence on the efficacy of antidepressants in this population is lacking. Because depression in patients with Parkinson's disease might be related to dopaminergic dysfunction, we aimed to assess the efficacy of the dopamine agonist pramipexole for treatment of depressive symptoms in patients with Parkinson's disease.Methods We did a 12-week randomised, double-blind, placebo-controlled (1:1 ratio) trial of pramipexole (0.125-1.0 mg three times per day) compared with placebo in patients with mild-to-moderate Parkinson's disease. Patients from 76 centres in 12 European countries and South Africa were included if they were on stable antiparkinsonian therapy without motor fluctuations and had depressive symptoms (15-item geriatric depression scale score > or =5 and unified Parkinson's disease rating scale [UPDRS] part 1 depression item score > or =2). Patients were randomly assigned by centre in blocks of four by use of a randomisation number generating system. Clinical monitors, the principal investigator, and patients were masked to treatment allocation. The primary endpoint was change in Beck depression inventory (BDI) score and all treated patients who had at least one post-baseline efficacy assessment were included in the primary analysis. We also did a pre-specified path analysis with regression models to assess the relation between BDI and UPDRS part 3 (motor score) changes. This trial is registered with ClinicalTrials.gov, number NCT00297778, and EudraCT, number 2005-003788-22.Findings Between March, 2006, and February, 2008, we enrolled 323 patients. Of 296 patients randomly assigned to pramipexole or placebo, 287 were included in the primary analysis: 139 in the pramipexole group and 148 in the placebo group. BDI scores decreased by an adjusted mean 5.9 (SE 0.5) points in the pramipexole group and 4.0 (0.5) points in the placebo group (difference 1.9, 95% CI 0.5-3.4; p=0.01, ANCOVA). The UPDRS motor score decreased by an adjusted mean 4.4 (0.6) points in the pramipexole group and 2.2 (0.5) points in the placebo group (difference 2.2, 95% CI 0.7-3.7; p=0.003, ANCOVA). Path analysis showed the direct effect of pramipexole on depressive symptoms accounted for 80% of total treatment effect (p=0.04). Adverse events were reported in 105 of 144 patients in the pramipexole group and 101 of 152 in the placebo group. Adverse events in the pramipexole group were consistent with the known safety profile of the drug.Interpretation Pramipexole improved depressive symptoms in patients with Parkinson's disease, mainly through a direct antidepressant effect. This effect should be considered in the clinical management of patients with Parkinson's disease.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(10)70106-x

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 44 references

Cited by

See all 638

Metadata

Authors
Barone, P., Poewe, W., Albrecht, S., Debieuvre, C., Massey, D., Rascol, O., Tolosa, E., & Weintraub, D.
Affiliations
  • University of Naples Federico II (IT)
  • Innsbruck Medical University (AT)
  • Boehringer Ingelheim (Germany) (DE)
  • Boehringer Ingelheim (France) (FR)
  • Inserm (FR)
  • Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
  • Mental Illness Research, Education and Clinical Centers (US)
Corresponding author
Barone, Paolo
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2010-06
Volume
9
Issue
6
Pages
573-580
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2152837663
Cited by
562
References
46
Citations by year
2026: 16 · 2025: 26 · 2024: 15 · 2023: 25 · 2022: 42 · 2021: 28 · 2020: 59 · 2019: 28 · 2018: 17 · 2017: 36 · 2016: 40 · 2015: 32 · 2014: 37 · 2013: 57 · 2012: 45
FWCI
30.11
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Boehringer Ingelheim
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords
Parkinson's disease, depression, dopamine agonists, antidepressant efficacy, dopaminergic dysfunction, motor symptoms, motor fluctuations, UPDRS motor score, Beck Depression Inventory, Geriatric Depression Scale, path analysis, antiparkinsonian therapy, adverse events
MeSH terms
Pramipexole, Aged, Antidepressive Agents, Antiparkinson Agents, Depressive Disorder, Double-Blind Method, Europe, Female, Humans, Male, Parkinson Disease, Psychiatric Status Rating Scales, Severity of Illness Index, South Africa, Time Factors, Treatment Outcome, Dopamine Agonists, Dyskinesias, Benzothiazoles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s1474-4422(10)70106-x
The paper
Barone, P., Poewe, W., Albrecht, S., Debieuvre, C., Massey, D., Rascol, O., Tolosa, E., & Weintraub, D. (2010). Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(10)70106-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.